Tumor Biology

, Volume 34, Issue 3, pp 1531–1536 | Cite as

Effect of lentinan combined with docetaxel and cisplatin on the proliferation and apoptosis of BGC823 cells

Research Article

Abstract

We studied the inhibitory effects of lentinan alone or lentinan combined with docetaxel and cisplatin on growth of gastric cancer cell line BGC823. The cells were divided into lentinan group, docetaxel combined with cisplatin group, and lentinan combined with docetaxel and cisplatin group. Gastric cancer cell line BGC823 was treated with different concentrations of drugs in each group. Tetrazolium-based colorimetric assay (MTT), Annexin V/propidium iodide method and flow cytometry were used to determine the proliferation and apoptosis of the cells in each group. The inhibition ratio was positively related with the concentrations of drugs when BGC823 cells were treated with docetaxel combined with cisplatin from low to high dose. The inhibition ratio of each group further increased after lentinan was added into the medium. The apoptosis rate of 6.25 μg/ml lentinan on BGC823 cells was 19.84 %. The apoptosis rate of BGC823 cells was significantly increased from 50.22 % to 72.06 % after treatment with 6.25 μg/ml lentinan combined with 2.5 μg/ml docetaxel and 50 μg/ml cisplatin. Lentinan has an inhibitory effect on the proliferation of gastric cancer cell line BGC823. Lentinan combined with docetaxel and cisplatin increases the inhibitory effect on the proliferation of BGC823 cells mediated by docetaxel combined with cisplatin. Low concentration of lentinan combined with docetaxel and cisplatin has better therapeutic effects on the proliferation of BGC823 cells compared with high concentrations of docetaxel combined with cisplatin. Lentinan has the ability of inducing BGC823 cell apoptosis and this effect is enhanced when combined with docetaxel and cisplatin.

Keywords

Lentinan Docetaxel Cisplatin Cell proliferation Gastric cancer cell line BGC823 

Notes

Conflicts of interest

None

References

  1. 1.
    Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci. 2010;14(4):302–8.PubMedGoogle Scholar
  2. 2.
    Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, et al. Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol. 2002;32(7):248–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature. 1969;222(5194):687–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Suga T, Shiio T, Maeda YY, Chihara G. Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res. 1984;44(11):5132–7.PubMedGoogle Scholar
  6. 6.
    Fujimoto K, Tomonaga M, Goto S. A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan. Anticancer Res. 2006;26(6A):4015–8.PubMedGoogle Scholar
  7. 7.
    Hamuro J. Anticancer immunotherapy with perorally effective lentinan. Gan To Kagaku Ryoho. 2005;32(8):1209–15.PubMedGoogle Scholar
  8. 8.
    Zhang LJQ, Ni ZH, Sun J. Prohibitin induces apoptosis in BGC823 gastric cancer cells through the mitochondrial pathway. Asian Pac J Cancer Prev. 2012;13:3803–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Ina K, Furuta R, Kataoka T, Kayukawa S, Yoshida T, Miwa T, et al. Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy. World J Clin Oncol. 2011;2(10):339–43. doi: 10.5306/wjco.v2.i10.339.PubMedCrossRefGoogle Scholar
  10. 10.
    Wang JL, Bi Z, Zou JW, Gu XM. Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. Mol Med Rep. 2012;5(3):745–8. doi: 10.3892/mmr.2011.718.PubMedGoogle Scholar
  11. 11.
    Kamano T, Mikami Y, Shirasaka T. Continuous infusion of 5-fluorouracil plus low-dose cisplatin in tumor-bearing mice. Anticancer Drugs. 1997;8(6):632–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol. 1996;6(1):443–57.PubMedGoogle Scholar
  13. 13.
    Kupfahl C, Geginat G, Hof H. Lentinan has a stimulatory effect on innate and adaptive immunity against murine Listeria monocytogenes infection. Int Immunopharmacol. 2006;6(4):686–96. doi: 10.1016/j.intimp.2005.10.008.PubMedCrossRefGoogle Scholar
  14. 14.
    Ina K, Ando T. The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem. 2012. doi:CMCACA-EPUB-20121018-2 [pii].Google Scholar
  15. 15.
    Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res. 2009;29(7):2739–45.PubMedGoogle Scholar
  16. 16.
    Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, et al. Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life. Hepatogastroenterology. 2009;56(90):547–50.PubMedGoogle Scholar
  17. 17.
    Hori T, Ikehara T, Takatsuka S, Fukuoka T, Tendo M, Tezuka K, et al. Combination chemotherapy of S-1/low-dose CDDP/lentinan for advanced gastric cancer. Gan To Kagaku Ryoho. 2011;38(2):293–5.PubMedGoogle Scholar
  18. 18.
    Murata T, Hatayama I, Kakizaki I, Satoh K, Sato K, Tsuchida S. Lentinan enhances sensitivity of mouse colon 26 tumor to cis-diamminedichloroplatinum (II) and decreases glutathione transferase expression. Jpn J Cancer Res. 1996;87(11):1171–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang L, Li X, Xu X, Zeng F. Correlation between antitumor activity, molecular weight, and conformation of lentinan. Carbohydr Res. 2005;340(8):1515–21. doi: 10.1016/j.carres.2005.02.032.PubMedCrossRefGoogle Scholar
  20. 20.
    Ng ML, Yap AT. Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes). J Altern Complement Med. 2002;8(5):581–9. doi: 10.1089/107555302320825093.PubMedCrossRefGoogle Scholar
  21. 21.
    Harada K, Itashiki Y, Takenawa T, Ueyama Y. Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo. Int J Oncol. 2010;37(3):623–31.PubMedCrossRefGoogle Scholar
  22. 22.
    Chen HL, Li DF, Chang BY, Gong LM, Piao XS, Yi GF, et al. Effects of lentinan on broiler splenocyte proliferation, interleukin-2 production, and signal transduction. Poult Sci. 2003;82(5):760–6.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of OncologyShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.Gastrointestinal Tumor Pathology Laboratory of Cancer Institute, Department of Tumor Pathology of General Surgery InstituteFirst Hospital of China Medical UniversityShenyang CityChina
  3. 3.China Medical UniversityShenyang CityChina

Personalised recommendations